None listed
Conditions
Brief summary
To describe clinical outcomes, demographics and assess satisfaction in patients that have been converted from warfarin to a NOAC (rivaroxaban or apixaban). Patient satisfaction will be assessed through the use of a survey utilising the Anti-Clot Treatment Scale questionnaire in addition to several questions focussing on the comparison between previous warfarin therapy and current NOAC therapy. These questions will relate to: medical contact, dietary restriction, drug interactions, travel, side effects, cost and overall satisfaction. Clinical outcomes will be described through retrospective review of patient medical notes.
Interventions
Retrospective cohort study with prospective assessment of medication satisfaction during NOAC therapy using the Anti-Clot Treatment Scale (ACTS). In addition, a supplementary questionnaire assessed patient’s relative satisfaction with NOAC therapy with their previous warfarin therapy. Retrospective review of patient medical records identified basic demographics and new adverse events.
Sponsors
The Perth Blood Institute
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
The population for this study consists of patients that have been changed from warfarin to a non-vitamin K antagonist oral anticoagulant (NOAC), rivaroxaban or apixaban, and are currently on one of these two medications. The population will be sourced from the patient pool of Professor Ross Baker at Haematology West, a private haematology practice in Nedlands, Western Australia.
Exclusion criteria
Patients discontinued or withheld NOAC treatment, re-switched to warfarin or other anticoagulants at the time of enrolment due to various reasons, and participants not willing to participate in the study or declined to answer the survey were excluded from the study.
Outcome results
None listed